| Identification | Back Directory | [Name]
TC-I 15 | [CAS]
916734-43-5 | [Synonyms]
TC-I 15
XKLHCUGVLCGKKX-RBUKOAKNSA-N
N-[[(4R)-5,5-Dimethyl-3-(phenylsulfonyl)-4-thiazolidinyl]carbonyl]-3-[[[(phenylmethyl)amino]carbonyl]amino]-L-alanine
L-Alanine, N-[[(4R)-5,5-dimethyl-3-(phenylsulfonyl)-4-thiazolidinyl]carbonyl]-3-[[[(phenylmethyl)amino]carbonyl]amino]- | [Molecular Formula]
C23H28N4O6S2 | [MDL Number]
MFCD26792566 | [MOL File]
916734-43-5.mol | [Molecular Weight]
520.62 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
Soluble to 100 mM in DMSO and to 25 mM in 1.1eq. NaOH | [form ]
Powder | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
TC-I 15 is an inhibitor of integrin α2β1, a collagen receptor. TC-I 15 has shown to prevent pathological thrombus formation . | [in vivo]
TC I-15 (10 μg; intravenous injection; every other day; for three weeks) inhibits lung metastasis promoted by CAFs EVs in mice[2]. | Animal Model: | C57BL/6 J mice[2] | | Dosage: | 10 μg; every other day for 3 weeks; once every 2 weeks for 3 weeks | | Administration: | Intravenous injection (i.v.) | | Result: | Inhibited the formation of pre-metastatic microenvironment induced by EVs, inhibited SACC lung metastasis induced by EVs, and significantly increased integrin β1 of EVs. |
| [IC 50]
α2β1: 0.4 (α2β1 μM (IC50); α2β1: 26.8 (α2β1 μM (IC50); α1β1: 23.6 (α1β1 μM (IC50); α1β1: 24.4 (α1β1 μM (IC50); α11β1: 177 (α11β1 μM (IC50); α11β1: 3177 (α11β μM (IC50) | [storage]
Store at -20°C |
|
|